Objetivo Silvercatpharma project aims at developing C-C cross-coupling reactions catalysed by d11-blocks metals, particularly silver, for the synthesis of pharmaceuticals in Novartis. It strives to have an impact in terms of cost, environment and international visibility because of the use of silver as an alternative catalyst. The project offers me a great opportunity to obtain further training, such as clusters preparation, computational and flow chemistry, and to define my final career in academia or industry because of the possibility of working in these two different environments. Ámbito científico natural scienceschemical sciencesorganic chemistrymedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsmedical and health sciencesbasic medicinemedicinal chemistrynatural scienceschemical sciencesinorganic chemistrytransition metalsnatural scienceschemical sciencescatalysis Programa(s) H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility Tema(s) MSCA-IF-2014-EF - Marie Skłodowska-Curie Individual Fellowships (IF-EF) Convocatoria de propuestas H2020-MSCA-IF-2014 Consulte otros proyectos de esta convocatoria Régimen de financiación MSCA-IF-EF-ST - Standard EF Coordinador FUNDACIO PRIVADA INSTITUT CATALA D'INVESTIGACIO QUIMICA Aportación neta de la UEn € 158 121,60 Dirección AVENIDA PAISSOS CATALANS 16 43007 Tarragona España Ver en el mapa Región Este Cataluña Tarragona Tipo de actividad Research Organisations Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Participación en los programas de I+D de la UE Opens in new window Red de colaboración de HORIZON Opens in new window Coste total € 158 121,60